In order to analyze the impact of SLC45A3 and PTEN alterations on ERG pathway activation, prostate tumors were divided in 2 groups depending on ERG immunohistochemical expression being positive (n = 103) or negative (n = 117). Here, PTEN is linked to prostate neoplasm.